Analyst firms · BofA Securities · STOK

BofA Securities STOK price target and rating history

Stoke Therapeutics Inc. (STOK) · Health Care

BofA Securities rates Stoke Therapeutics Inc. (STOK) Neutral with a $12 price target, as of its latest action on May 1, 2023. It has published 3 rating actions on STOK since December 2021, including 1 upgrade and 1 downgrade. Across 4 firms with a STOK price target in the last 12 months, the median target is $42.

Current rating
Neutral
Price target
$12
Median target, all firms
$42
Actions on STOK
3

BofA Securities price target on STOK

$22$15$920222023202420252026
BofA Securities price target on STOK, each point a stated target, December 2021 to May 2023. Targets before January 2023 (divided by 2) are adjusted for a stock split, going by the prior target BofA Securities restated.

Every BofA Securities rating on STOK

How other firms rate STOK

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Goldman SachsBuy$44Jul 13, 2026
Wolfe ResearchOutperform$40Feb 24, 2026
GuggenheimBuy$60Feb 5, 2026
Chardan Capital MarketsBuy$35Jan 5, 2026

Questions about BofA Securities and STOK

What is BofA Securities's price target for STOK?
BofA Securities's latest stated price target for Stoke Therapeutics Inc. (STOK) is $12, from its action on May 1, 2023.
What is BofA Securities's rating on STOK?
BofA Securities rates STOK Neutral, a neutral rating, as of May 1, 2023.
When did BofA Securities last change its view on STOK?
On May 1, 2023, BofA Securities upgrades to Neutral from Underperform, price target $9 to $12.
How does BofA Securities's STOK target compare with other analysts?
Across 4 firms with a STOK price target in the last 12 months, the median target is $42.

All BofA Securities ratingsSTOK news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.